Close Menu

NEW YORK (GenomeWeb) – Epigenomics of Germany said today that it has terminated its collaboration with China's BioChain for the licensing of the Septin9 marker and exclusive Chinese distribution rights for Epi proColon, Epigenomics' blood test for colorectal cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.